TY - JOUR
T1 - Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial
T2 - A randomized controlled study
AU - Noe, Megan H.
AU - Wan, Marilyn T.
AU - Shin, Daniel B.
AU - Armstrong, April W.
AU - Duffin, Kristina Callis
AU - Chiesa Fuxench, Zelma C.
AU - Kalb, Robert E.
AU - Menter, Alan
AU - Simpson, Eric L.
AU - Takeshita, Junko
AU - Tyring, Stephen K.
AU - Van Voorhees, Abby S.
AU - Mehta, Nehal N.
AU - Gelfand, Joel M.
N1 - Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Background: There are limited data about the impact of narrowband ultraviolet B phototherapy on patient-reported measures of health-related quality of life. Objective: To evaluate the impact of adalimumab and phototherapy on health-related quality of life. Methods: We examined patient-reported outcomes from a multicenter, randomized, placebo-controlled trial (ClinicalTrials.gov no. NCT01553058). The Dermatology Life Quality Index and EQ-5D-3L were evaluated every 4 weeks. Results: We enrolled 97 patients: 30.9% were female, mean age was 43.5 years (standard deviation, 14.0), and median Psoriasis Area and Severity Index score was 16.7 (interquartile range, 13.9-21.6). At week 12, patients being treated with adalimumab (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.02-8.17) and phototherapy (OR, 8.83; 95% CI, 2.47-31.57) were more likely to achieve the minimal clinically important difference in the Dermatology Life Quality Index compared with those receiving placebo. There were higher odds of achieving the minimal clinically important difference for the EQ-5D-3L Index score when comparing phototherapy versus placebo (OR, 9.78; 95% CI, 2.99-31.95) and phototherapy versus adalimumab (OR, 4.07; 95% CI, 1.42-11.70). Limitations: Small sample size, secondary analysis, generalizability. Conclusion: Phototherapy and adalimumab both improve skin-related quality of life and overall health-related quality of life compared with placebo in patients with psoriasis; however, patients treated with phototherapy achieved more improvement in overall health-related quality of life compared with patients treated with adalimumab.
AB - Background: There are limited data about the impact of narrowband ultraviolet B phototherapy on patient-reported measures of health-related quality of life. Objective: To evaluate the impact of adalimumab and phototherapy on health-related quality of life. Methods: We examined patient-reported outcomes from a multicenter, randomized, placebo-controlled trial (ClinicalTrials.gov no. NCT01553058). The Dermatology Life Quality Index and EQ-5D-3L were evaluated every 4 weeks. Results: We enrolled 97 patients: 30.9% were female, mean age was 43.5 years (standard deviation, 14.0), and median Psoriasis Area and Severity Index score was 16.7 (interquartile range, 13.9-21.6). At week 12, patients being treated with adalimumab (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.02-8.17) and phototherapy (OR, 8.83; 95% CI, 2.47-31.57) were more likely to achieve the minimal clinically important difference in the Dermatology Life Quality Index compared with those receiving placebo. There were higher odds of achieving the minimal clinically important difference for the EQ-5D-3L Index score when comparing phototherapy versus placebo (OR, 9.78; 95% CI, 2.99-31.95) and phototherapy versus adalimumab (OR, 4.07; 95% CI, 1.42-11.70). Limitations: Small sample size, secondary analysis, generalizability. Conclusion: Phototherapy and adalimumab both improve skin-related quality of life and overall health-related quality of life compared with placebo in patients with psoriasis; however, patients treated with phototherapy achieved more improvement in overall health-related quality of life compared with patients treated with adalimumab.
KW - DLQI
KW - EQ5D
KW - adalimumab
KW - patient-reported outcomes
KW - phototherapy
KW - psoriasis
KW - randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=85070247060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070247060&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.05.080
DO - 10.1016/j.jaad.2019.05.080
M3 - Article
C2 - 31163241
AN - SCOPUS:85070247060
SN - 0190-9622
VL - 81
SP - 923
EP - 930
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -